Related Experiment Video
Updated: Jul 18, 2026
An Efficient Method for Adenovirus Production
Published on: June 10, 2021
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter
W M Gommans1, P M J McLaughlin, J A C Schalk
1Department of Therapeutic Gene Modulation, Groningen University Institute for Drug Exploration, The Netherlands.
Abstract:
Although some successes have been reported using adenoviral vectors for the treatment of cancer, adenoviral cancer gene therapy is still hampered by the lack of sufficient tumor cell killing. To increase the efficiency, adenoviruses have been modified to replicate specifically in tumor tissues by using tumor specific promoters controlling genes essential for adenoviral replication. However, many conditionally replicating adenoviral vectors replicate in one tumor type only, which limits their application. The epithelial glycoprotein-2 (EGP-2) promoter is active in a broad variety of carcinomas, the most common type of cancer. We utilized this promoter to restrict adenoviral replication. In this report we demonstrate that the potency of the replication-competent adenovirus AdEGP-2-E1 to specifically lyse EGP-2 positive cells is comparable to wild-type adenovirus (AdWT). In addition, we show that in vivo AdEGP-2-E1 replicates as efficient as AdWT in EGP-2 positive tumor cells. On the contrary, in EGP-2 negative cell lines as well as in primary human liver samples, the replication was attenuated up to 4-log in comparison to wild-type virus. This report clearly shows the potency of the EGP-2 promoter to mediate highly efficient and specific adenoviral replication for carcinoma gene therapy.
Insights
This study developed a novel oncolytic adenovirus using the EGP-2 promoter for enhanced cancer gene therapy. The engineered virus effectively targets and kills cancer cells while sparing healthy tissues.
Area of Science:
- Oncolytic virotherapy
- Molecular and cellular oncology
- Gene therapy
Background:
- Adenoviral vectors show promise in cancer gene therapy but often lack sufficient tumor cell killing.
- Current conditionally replicating adenoviruses are often limited to specific tumor types.
- Tumor-specific promoters can enhance adenoviral replication selectively in cancer cells.
Purpose of the Study:
- To engineer an oncolytic adenovirus with tumor-specific replication using the epithelial glycoprotein-2 (EGP-2) promoter.
- To evaluate the efficacy and specificity of the AdEGP-2-E1 vector in targeting carcinoma cells.
Main Methods:
- Utilized the EGP-2 promoter to control essential adenoviral replication genes.
- Constructed a replication-competent adenovirus, AdEGP-2-E1.
- Compared the replication and cell-killing ability of AdEGP-2-E1 to wild-type adenovirus (AdWT) in EGP-2 positive and negative cells, and in vivo.
Main Results:
- AdEGP-2-E1 demonstrated potent and specific lysis of EGP-2 positive cancer cells, comparable to AdWT.
- In vivo studies showed AdEGP-2-E1 replicated efficiently in EGP-2 positive tumors.
- Replication of AdEGP-2-E1 was significantly attenuated (up to 4-log) in EGP-2 negative cells and human liver samples.
Conclusions:
- The EGP-2 promoter effectively restricts adenoviral replication to EGP-2 positive tumor cells.
- AdEGP-2-E1 shows significant potential for targeted carcinoma gene therapy.
- This approach enhances the specificity and safety of oncolytic adenoviral vectors.
